Not a good buy right now for an impatient investor: the broader trend remains bearish (SMA_200 > SMA_20 > SMA_5) and price is still below the key pivot/resistance zone (~15.02).
Upside exists (BofA Buy with $22 PT), but without fresh catalysts/news and with no proprietary buy signals today, the risk/reward for an immediate entry is not compelling.
Trend/Momentum: Bearish structure (SMA_200 > SMA_20 > SMA_5) suggests rallies may face selling pressure.
MACD: Histogram -0.13 (below zero) but negatively contracting, implying downside momentum is weakening (possible basing attempt, not a confirmed reversal).
RSI(6): 43.64 (neutral-to-soft), indicating no strong oversold bounce signal.
Levels:
Support: S1 14.385 then S2 13.993 (price 14.745 is only modestly above first support).
Resistance/Pivot: 15.019 (first “line in the sand” for reclaiming bullish control), then R1 15.653.
Pattern-based projection provided: ~70% chance of a small move next day, slightly negative next week, but +5.12% next month—supports a potential swing recovery, but timing is not favorable today without a trigger above ~15.02.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI ratio = 0.5 (call OI 225 vs put OI 113) → mildly bullish positioning.
Activity (Volume): Extremely light (total volume 10; calls 0, puts 10). Sentiment from today’s flow is low-confidence due to thin trading.
Volatility: IV30 = 121.62 vs Historical Vol = 36.57 → options are pricing very large moves; IV percentile 32 suggests IV is not at extremes versus its own history, and IV has been drifting down vs 5–10d averages (137).
Technical Summary
Sell
3
Buy
9
Positive Catalysts
despite the cut.
Neutral/Negative Catalysts
Primary trend is still bearish (moving averages stacked bearishly), making this a lower-probability “buy-right-now” setup.
Price is below the pivot/resistance (~15.02); failure to reclaim it can keep the stock range-bound or drifting lower.
No recent news catalysts in the last week to drive a decisive re-rating.
No notable hedge fund or insider accumulation signals in the provided trend data (both neutral).
Options market is thin today; volume is too low to strongly confirm bullish conviction.
Financial Performance
Latest quarter financials not available in the provided data (financial snapshot error), so growth trends and the latest quarter/season cannot be assessed here.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
[2026-01-06] BofA: Buy maintained, price target lowered to $22 from $25.
Wall Street pros/cons view (from provided coverage):
Pros: constructive broader biotech backdrop (data catalysts being rewarded, improved access to capital, M&A/in-licensing demand).
Cons: target cut indicates some moderation in expectations; durability of the biotech rebound is cited as a key concern.
Net takeaway: analyst stance is supportive, but not enough to override the current bearish technical posture for an immediate entry.
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 22 USD with a low forecast of 22 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCM is 22 USD with a low forecast of 22 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.570
Low
22
Averages
22
High
22
Current: 14.570
Low
22
Averages
22
High
22
BofA
Buy
downgrade
$25 -> $22
AI Analysis
2026-01-06
Reason
BofA
Price Target
$25 -> $22
AI Analysis
2026-01-06
downgrade
Buy
Reason
BofA lowered the firm's price target on Hutchmed to $22 from $25 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.
Morgan Stanley
Equal Weight -> Underweight
downgrade
$18
2025-09-22
Reason
Morgan Stanley
Price Target
$18
2025-09-22
downgrade
Equal Weight -> Underweight
Reason
Morgan Stanley downgraded Hutchmed to Underweight from Equal Weight with a price target of $13.75, down from $18. The company reduced its commercial guidance amid a restructuring and its \"lackluster\" near-term growth could drive a valuation de-rating, the analyst tells investors in a research note. The firm says Hutchmed's approved assets could be entering a period of declining product life cycles and patent expirations.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HCM
